Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 12;19(1):67.
doi: 10.1186/s12884-019-2206-x.

Full versus half dose of antenatal betamethasone to prevent severe neonatal respiratory distress syndrome associated with preterm birth: study protocol for a randomised, multicenter, double blind, placebo-controlled, non-inferiority trial (BETADOSE)

Thomas Schmitz  1   2   3 , Corinne Alberti  4   5   6 , Moreno Ursino  7 , Olivier Baud  8   9 , Camille Aupiais  4   6   7   10 ; BETADOSE study group and the GROG (Groupe de Recherche en Gynécologie Obstétrique)
Affiliations

Full versus half dose of antenatal betamethasone to prevent severe neonatal respiratory distress syndrome associated with preterm birth: study protocol for a randomised, multicenter, double blind, placebo-controlled, non-inferiority trial (BETADOSE)

Thomas Schmitz et al. BMC Pregnancy Childbirth. .

Abstract

Background: Although antenatal betamethasone is recommended worldwide for women at risk of preterm delivery, concerns persist regarding the long-term effects associated with this treatment. Indeed, adverse events, mainly dose-related, have been reported. The current recommended dose of antenatal betamethasone directly derives from sheep experiments performed in the late 60's and has not been challenged in 45 years. Therefore, randomized trials evaluating novel dose regimens are urgently needed.

Methods: A randomised, double blind, placebo-controlled, non-inferiority trial will be performed in 37 French level 3 maternity units. Women with a singleton pregnancy at risk of preterm delivery before 32 weeks of gestation having already received a first 11.4 mg injection of betamethasone will be randomised to receive either a second injection of 11.4 mg betamethasone (full dose arm) or placebo (half dose arm) administered intramuscularly 24 h after the first injection. The primary binary outcome will be the occurrence of severe respiratory distress syndrome (RDS), defined as the need for exogenous intra-tracheal surfactant in the first 48 h of life. Considering that 20% of the pregnant women receiving the full dose regimen would have a neonate with severe RDS, 1571 patients in each treatment group are required to show that the half dose regimen is not inferior to the full dose, that is the difference in severe RDS rate do not exceed 4% (corresponding to a Relative Risk of 20%), with a 1-sided 2.5% type-1 error and a 80% power. Interim analyses will be done after every 300 neonates who reach the primary outcome on the basis of intention-to-treat, using a group-sequential non-inferiority design.

Discussion: If the 50% reduced antenatal betamethasone dose is shown to be non-inferior to the full dose to prevent severe RDS associated with preterm birth, then it should be used consistently in women at risk of preterm delivery and would be of great importance to their children.

Trial registration: ClinicalTrials.gov identifier: NCT 02897076 (registration date 09/13/2016).

Trial registration: ClinicalTrials.gov NCT02897076.

Keywords: Antenatal betamethasone; Antenatal corticosteroids; Non-inferiority; Preterm birth; Preterm delivery; Respiratory distress syndrome.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Ethics approval was granted by the Committee for the Protection of People participating to biomedical research Ile-de-France 1 (#14242ND, June, 26th 2016) and the National Agency for Drug Security (#160457A-22, May, 25th 2016). Women were included and randomized in the BETADOSE trial only after written informed consent to participate was obtained.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow chart of the trial
See this image and copyright information in PMC

References

    1. Liggins GC. Premature delivery of foetal lambs infused with glucocorticoids. J Endocrinol. 1969;45:515–523. doi: 10.1677/joe.0.0450515. - DOI - PubMed
    1. Liggins GC, Higgins RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50:515–525. - PubMed
    1. Crowley PA. Antenatal corticosteroid therapy: a meta-analysis of the randomised trials, 1972 to 1994. Am J Obstet Gynecol. 1995;173:322–335. doi: 10.1016/0002-9378(95)90222-8. - DOI - PubMed
    1. National Institutes of Health Consensus Development Conference Statement Effect of corticosteroids for fetal maturation on perinatal outcomes. Am J Obstet Gynecol. 1995;173:246–252. doi: 10.1016/0002-9378(95)90208-2. - DOI
    1. ACOG committee opinion Antenatal corticosteroid therapy for fetal maturation. Number 147--December 1994. Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1995;48:340–342. doi: 10.1016/0020-7292(95)90313-5. - DOI - PubMed

Associated data